Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

Not Applicable

Not yet recruiting

• Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)

• Registration Number: NCT06984562
• Lead Sponsor: Fox Chase Cancer Center

Brief Summary

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

The main questions the study aims to answer are:

* Can ART improve how well radiation therapy targets the most aggressive cancer cells, while protecting the healthy tissue around the tumor?

* Can ART help reduce the side effects that participants may experience during treatment?

Participants will:

* Undergo CT scans to plan the exact location of the radiation treatment. During this process, 1-3 small markers may be placed in or near the tumor to help with the planning.

* Have a tumor biopsy, which involves taking a small sample of tissue from the cancer.

* Receive 5 radiation treatments every other day over a 2-week period.

* Provide blood samples before, during, and after your radiation treatment.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-05
• Study First Submitted: 2025-05-13
• Study First Submitted QC: 2025-05-20
• Last Update Submitted: 2025-05-20
• Study First Posted: 2025-05-22
• Last Update Posted: 2025-05-22
• Study Start: 2025-08-01
• Primary Completion: 2028-08-01
• Study Completion: 2029-08-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
The rate of acute and late grade ≥3 gastrointestinal toxicity occurring within 3 months of treatment possibly, probably or definitely related to radiation.	From start of radiation to 3 months after the end of radiation treatment

Secondary Outcome Measures

Name	Time	Method
The proportion of patients experiencing local control defined as stable disease or any response at the radiation target site(s).	From the start of radiation to 5 years after end of radiation treatment
Overall Survival Rate - defined as the time from the start of radiation to death or last contact. Individuals who are alive at last follow-up will be considered censored at the time of last contact.	From the start of radiation to death or last contact (up to 5 years after end of treatment).
The rate of acute and late adverse events at time points prescribed in the study calendar using CTCAE version 5.0.	From start of radiation to end of long-term follow up (up to 5 years)

Trial Locations

Locations (1)

Fox Chase Cancer Center; 🇺🇸 Philadelphia, Pennsylvania, United States